Psychedelics surge again as Compass, Definium provide more clinical validation
BioSpace reports: Psychedelics surge again as Compass, Definium provide more clinical validation.
Definium Therapeutics
Clinical-stage psychedelics company developing LSD-based therapies for major depressive disorder and other psychiatric conditions.
Company Info
Sector:Psychedelics & Related
Headquarters:San Diego, California, USA
Founded:2020
Website:definiumtx.com/
Upcoming Milestones & Key Dates
2026 H2
Clinical readout
Phase 3 topline data (DT-120 MDD)
2027 H1
Regulatory filing
NDA submission for DT-120
Clinical Development Pipeline
DT-120
Target: 5-HT2A agonist (LSD)DT-220
Target: 5-HT2A agonistDT-310
Target: 5-HT2A agonistRecent News
Definium's LSD-based therapy elicits 'profound' efficacy in Phase 3 depression trial
Definium Therapeutics reported Phase 3 results showing its LSD-based therapy elicited 'profound' efficacy in treatment-resistant depression, marking a notable psychedelic-pharma readout.
Definium reports Phase 3 hit for LSD drug in severe depression
Definium Therapeutics' LSD-based therapy showed 'profound' efficacy in a late-stage trial in major depressive disorder.
Leadership Team
Robert Barrow
Chief Executive Officer
Careers & Job Openings